Corrections to: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.


Journal

Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585

Informations de publication

Date de publication:
24 Jun 2019
Historique:
received: 14 06 2019
accepted: 14 06 2019
entrez: 26 6 2019
pubmed: 27 6 2019
medline: 27 6 2019
Statut: epublish

Résumé

Following publication of the original article [1], the authors reported an error in the Acknowledgments section. It should be read: 'We are grateful to Mohsin Shah from the Department of Emergency Medicine at The University of Texas MD Anderson Cancer Center for assisting in study selection, and to Gregory F. Pratt from the Research Medical Library and Erica Goodoff, from the Department of Scientific Publications at The University of Texas MD Anderson Cancer Center for their valuable contributions.

Identifiants

pubmed: 31234936
doi: 10.1186/s40425-019-0639-4
pii: 10.1186/s40425-019-0639-4
pmc: PMC6589871
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

158

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States

Commentaires et corrections

Type : ErratumFor

Références

J Immunother Cancer. 2019 Apr 16;7(1):106
pubmed: 30992053

Auteurs

Noha Abdel-Wahab (N)

Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt.

Houssein Safa (H)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Ala Abudayyeh (A)

Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Daniel H Johnson (DH)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Van Anh Trinh (VA)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Chrystia M Zobniw (CM)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Heather Lin (H)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Michael K Wong (MK)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Maen Abdelrahim (M)

Houston Methodist Hospital, Houston, TX, USA.

A Osama Gaber (AO)

Houston Methodist Hospital, Houston, TX, USA.

Maria E Suarez-Almazor (ME)

Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Adi Diab (A)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. adiab@mdanderson.org.

Classifications MeSH